BCL3ANT

BCL3ANT
Identifiers
	IUPAC name 2-[[[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]amino]methylidene]propanediamide;
CAS Number	910855-84-4;
PubChem CID	377887;
ChemSpider	335043;
ChEMBL	ChEMBL1617694;
Chemical and physical data
Formula	C13H10Cl2N4O2S
Molar mass	357.21 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=C(C=C1C2=CSC(=N2)NC=C(C(=O)N)C(=O)N)Cl)Cl;
	InChI InChI=1S/C13H10Cl2N4O2S/c14-8-2-1-6(3-9(8)15)10-5-22-13(19-10)18-4-7(11(16)20)12(17)21/h1-5H,(H2,16,20)(H2,17,21)(H,18,19); Key:NYUREPFBBIUCSR-UHFFFAOYSA-N;

BCL3ANT is an experimental anticancer drug which acts as an inhibitor of BCL3-mediated expression of cyclin D1, which is important for the proliferation and metastasis of certain types of cancer such as lymphoma and melanoma. BCL3ANT is of relatively low potency and is unlikely to be developed as a medicine in its own right, however as the first drug developed which inhibits BCL3-mediated cyclin D1 expression it is of academic interest in this area and is likely to lead to the development of more potent drugs acting through this pathway, which may be useful as anticancer medications.^[1]

References

↑ Saamarthy K, Ahlqvist K, Daams R, Balagunaseelan N, Rinaldo-Matthis A, Kazi JU, et al. (January 2024). "Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells". BMC Cancer. 24 (1) 103. doi:10.1186/s12885-023-11663-y. PMC 10795364. PMID 38238702.

[pmid38238702-1] Saamarthy K, Ahlqvist K, Daams R, Balagunaseelan N, Rinaldo-Matthis A, Kazi JU, et al. (January 2024). "Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells". BMC Cancer. 24 (1) 103. doi:10.1186/s12885-023-11663-y. PMC 10795364. PMID 38238702.

[1]

This page was redesigned at the edge.

A page that knows where it met you.

BCL3ANT

References